Medicare challenges and solutions - Reimbursement issues in treating the patient with colorectal cancer

Journal of Managed Care Pharmacy

Volumn 13, Issue 6 SUPPL. C, 2007, Pages

  Kaa, Kathleen ^a  

^a Lash Group   (United States)

Author keywords

Cancer therapies; Coverage gap; Medicare coverage; Medicare Part D; Medicare reform; Off label prescribing

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; GENERIC DRUG; IRINOTECAN; OXALIPLATIN;

BUDGET; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE MANAGEMENT; HUMAN; MEDICAL FEE; MEDICARE; OFF LABEL DRUG USE; PRESCRIPTION; REIMBURSEMENT; REVIEW;

EID: 35348948052     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s6-c.19     Document Type: Review

References (23)

1. National Cancer Institute. Surveillance, epidemiology and end results: colon and rectal cancer fast facts. Available at: http://seer.cancer.gov/ faststats/sites.php?stat=Incidence&site=Colon+and+Rectum+Cancer&x= 9&y=18. Accessed October 1, 2006.
2. Lash Group Healthcare Consultants. 2003 HCUP inpatient sample [in-house analysis].
3. Centers for Medicare & Medicaid Services. Decision memo for anticancer chemotherapy for colorectal cancer (CAG-00179N). January 28, 2005. Available at: http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=90. Accessed October 20, 2006.
4. Social Security Administration. Compilation of the Social Security laws. Part E - miscellaneous provisions: definitions of services, institutions, etc (SEC. 1861. [42 U.S.C. 1395x]). Available at: http://www.ssa.gov/OP_Home/ssact/ title18/1861.htm. Accessed October 20, 2006.
5. Centers for Medicare & Medicaid Services. Medicare coverage database. NCD for anti-cancer chemotherapy for colorectal cancer (110.17). April 18, 2005. Publication no. 13-3. Available at: http://www.cms.hhs.gov/mcd/ cpt_license.asp?type=ncd&page=index_list.asp&where=index_list. asp|ncd&ncd_id=110.17&ncd_version=1&basket=ncd:110.17:1: Anti%2DCancer+Chemotherapy+for+Colorectal+Cancer. Accessed April 5, 2007.
6. U.S. Food and Drug Administration. Oncology tools: Fast track, priority review and accelerated approval. Available at: http://www.accessdata.fda.gov/ scripts/cder/onctools/Accel.cfm. Accessed October 1, 2006.
7. Centers for Medicare & Medicaid Services. Medicare announces draft guidance for national coverage determinations with evidence development [news release]. April 7, 2005. Available at: http://www.cms.hhs.gov/apps/media/press/ release.asp?Counter=1423. Accessed March 22, 2007.
8. Pub L No 108-173, 117 Stat 2066 (§811) of Medicare Prescription Drug Improvement, and Modernization Act of 2003 (MMA 2003).
9. Centers for Medicare & Medicaid Services (CMS). Medicare Advantage/Part D contract and enrollment data. Available at: http://www.cms.hhs.gov/MCRAdvPartDEnrolData/. Accessed October 14, 2006.
10. The Actuarial Research Corporation for the Kaiser Family Foundation. Prescription drug spending under the MMA: modeling the impact on out-of-pocket costs. November, 2006. Available at: http://www.kff.org/medicare/med112204pkg. cfm. Accessed October 30, 2006.
11. Schrag D. The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-19.
12. Medical Payment Advisory Commission. Testimony: Medicare Part B drugs and oncology. July 13, 2006. Available at: http://www.medpac.gov/publications/ congressional_testimony/071306_Testimony_Part%20B_oncology.pdf. Accessed October 30, 2006.
13. Medicare Reimbursement Guide Monthly Dispatch. CMS to cut Part B physician reimbursement rates for 2007. Rockville, MD: FDC Reports. December 2006. Available at: http://www.medicarerxguide.com/mdrg/mdrg0612.pdf. Accessed April 15, 2007.
14. Farber M. The Association of Community Cancer Centers: legislative update. Presented at: ACCC's 33rd Annual National Meeting; March 31, 2007; Baltimore, MD. Available at: http://www.accc-cancer.org/meet/pdf/ meet_annual07_farber2.pdf. Accessed April 15, 2007.
15. 71 Federal Register 77,174 (December. 22, 2006).
16. CMS releases AMP proposed rule, proposes significant changes in AMP and best price reporting. Sidley Health Industry Update. January 2007; 7(1). Rockville, MD: Sidley Austin LLP; 2007. Available at: http://www.sidley.com/ db30/cgi-bin/pubs/HealthCareUpdate010907.pdf. Accessed March 15, 2007.
17. Centers for Medicaid & Medicare Services. ICD-9-CM official guidelines for coding and reporting. Available at: http://www.cdc.gov/nchs/ datawh/ftpserv/ftpicd9/icdguide06.pdf. Accessed April 16, 2007.
18. Centers for Medicaid & Medicare Services. ICD-9 provider & diagnostic codes: ICD-10-PCS coding system and reference manual. Available at: http://www.cms.hhs.gov/ICD9ProviderDiagnosticCodes/08_ICD10.asp#TopOfPage. Accessed March 25, 2007.
19. Many Medicare prescription drug benefit beneficiaries in plans without "donut hole" coverage gap, study findings. Tricare News. November 23, 2006. Available at: http://www.medicalnewstoday.com/medicalnews. php?newsid=57252. Accessed April 30, 2007.
20. Cubanski J, Neuman P. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff. 2007;26(1):w1-w12. Available at: http://content.healthaffairs.org/cgi/content/ abstract/hlthaff.26.1.w1?ijkey=rqXm20BRs2tTc&keytype=ref&siteid= healthaff. Accessed on April 30, 2007.
21. Kaisernetworks.org. Medicare: few private insurance plans provide brand-name prescription drug coverage during Medicare "donut hole." Daily Health Pol Rep. April 2, 2007. Available at: http://www. kaisernetwork.org/daily_reports/rep_index.cfm?hint=3&DR_ID=44000. Accessed April 15, 2007.
22. Alonso-Saldivar R. Brand-name Medicare drug needs are going unmet: the private sector was supposed to help bridge a $3,000 coverage gap. But beneficiaries' options are few - and dwindling. Los Angeles Times. April 2, 2007:A10.
23. Butcher L. No extension for CMS demo project. Oncology Times. 2007;29(2):7.